Pierre Lemieux

Technologie BiolActis, Inc. engages in the development of biologics for the wellness industries. It specializes in the development of natural peptide mixtures for treatment and prevention of diseases like lipid and cardio-vascular disorders and metabolic syndrome. The company was founded by Eric M. Simard and Pierre Lemieux in 1998 and is headquartered in Laval, Canada.

Part of Quintiles Transnational Corp., PharmaBio Development, Inc. operates as an investment company. The company is based in Durham, NC. Dennis B. Gillings has been the CEO of the company since 2016.

Supratek Pharma, Inc. develops drugs and related oncology therapeutic products. It offers injectable chemotherapeutic that enhances or enables an approved anticancer drug. The firm’s products include SP1014C - a novel cabazitaxel against drug resistant prostate cancer, SP1030C - novel bendamustine against chronic lymphocytic leukemia and non-Hodgkin’s lymphoma and SP1049C - a novel injectable anthracycline platform drug against chemoresistant cancers. The company was founded by Valery Alakhov in 1994 and is headquartered in Pointe-Claire, Canada.

BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun.